Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.76 |
| ▸ | PDE1A | P54750 | 7/20 | 0.45 |
| ▸ | PDE5A | O76074 | 5/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.45 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7874358 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL4919936 | 0.84 | PDE1A (0.56) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL7874805 | 0.75 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7874354 | 0.72 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL13333242 | 0.71 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL12281572 | 0.70 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL4551320 | 0.70 | PDE5A (0.63) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL17508436 | 0.70 | PDE1A (0.54) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL4925794 | 0.68 | PDE1A (0.47) | PDE4APDE4BPDE4CPDE4DPDE1A | |
| SCHEMBL15255671 | 0.68 | PDE1A (0.56) | PDE4APDE4BPDE4CPDE4DPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10238660-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160375028-A1 | ORGANIC COMPOUNDS | FIENBERG ALLEN A (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2010132127-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010098839-A1 | PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2008070095-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008063505-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE4B 8/4885PDE4C 11/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | PDE4A 8/4885PDE4B 22/4885PDE4C 19/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE4B 8/4885PDE4C 11/4885 |
| US-20160375028-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE4B 8/4885PDE4C 11/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | PDE4A 8/4885PDE4B 9/4885PDE4C 16/4885 |
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | PDE12, PDE5A, PDE3A | PDE4A 6/4885PDE4B 12/4885PDE4C 11/4885 |
| US-10238660-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE4A 2/4885PDE4B 8/4885PDE4C 11/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE4A 9/4885PDE4B 24/4885PDE4C 19/4885 |
| US-11464781-B2 | PDE1 inhibitors for ophthalmic disorders | PDE12, PDE5A, PDE3A | PDE4A 6/4885PDE4B 12/4885PDE4C 11/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | PDE4A 10/4885PDE4B 25/4885PDE4C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.